Physician profile
Christopher Wade
NPI 1568425924
$1,414.92
in general payments reported to CMS, 2019-2025
11 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $464 · 2023: $392 · 2024: $305 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $811.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $487.39 | 2022-2024 | Ingrezza |
| Novo Nordisk INC | $362.06 | 2021-2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $271.59 | 2022-2024 | Eliquis |
| Lilly USA, LLC | $57.35 | 2025 | Zepbound, Mounjaro |
| Acerus Pharmaceuticals Corporation | $47.91 | 2022 | |
| Eisai INC. | $43.66 | 2021 | |
| Boston Scientific Corporation | $38.35 | 2024 | Watchman Access System |
| Antares Pharma, INC. | $37.61 | 2022 | |
| Abbvie INC. | $29.68 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.39 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.93 | 2023 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.